“Establishing a Risk Model for Diabetic Nephropathy and Addressing the Therapeutic Effect of Combined Epalrestat- Dapagliflozin Regimen”. 2024.
Iranian Journal of Kidney Diseases
18 (05).
https://doi.org/10.52547/ax1vqh41
.